ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Clopidogrel

Also written as “clopidogrel”, “clopidogrel (SR25990C)” and “Clopidogrel (SR25990)”.

Its studies are mostly in Coronary Artery Disease · Cardiovascular Diseases · Acute Coronary Syndrome · Heart Defects, Congenital · Diabetes Mellitus, Type 2, led by 17 companies.

Drug pageClopidogrel: every studyMany companies study it; this page follows only the 55 they lead. All 341 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 23, 200655 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only250 open or runningphase 4since Feb 23, 2006Dec 20, 2002none ahead
Dr. Reddy's Laboratoriesits history only40 open or runningphase 1since Jan 6, 2012Jan 6, 2012none ahead
AstraZenecaits history only30 open or runningphase 1since Jun 4, 2010Jun 4, 2010none ahead
Bristol-Myers Squibbits history only30 open or runningphase 1since Jul 8, 2009Jul 8, 2009none ahead
Eli Lillyits history only30 open or runningphase 2since Jul 26, 2006Jul 26, 2006none ahead
Viatrisits history only30 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Johnson & Johnsonits history only20 open or runningphase 2since Nov 13, 2014Nov 13, 2014none ahead
Les Laboratoires des Médicaments Stérilesits history only20 open or runningphase 4since Aug 25, 2011Aug 25, 2011none ahead
Merckits history only20 open or runningphase 1since Nov 10, 2009Nov 10, 2009none ahead
Accumetricsits history only10 open or runningno phasesince Mar 24, 2008Mar 24, 2008none ahead
Cordis10 open or runningphase 4since Aug 6, 2009Aug 6, 2009none ahead

Also a collaborator on its studies: Bayer and Daiichi Sankyo.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Cordis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2009First study: phase 4 study in Coronary Artery DiseaseFirst studyNCT00954707 · 2,509 enrolled · United States

TargetBeta

P2RY12 →read by rule
“Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist”ChEMBL 37, by rule

Other programs on P2RY12

ProgramCompanyFurthest phaseStudies
TicagrelorruleAstraZenecaphase 447
selatogrelruleViatrisphase 311

Studies

The one study Cordis leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00954707Coronary Artery Disease · United States4UNKNOWNJan 20122,509

How it is read

Names in the registry

  • “Clopidogrel”, 41 entries
  • “clopidogrel”, 11 entries
  • “clopidogrel (SR25990C)”, 4 entries
  • “Clopidogrel (SR25990)”, 3 entries
  • “clopidogrel (SR25990)”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.